The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels

被引:0
|
作者
Kerb R. [1 ]
Aynacioglu A.S. [2 ,3 ]
Brockmöller J. [2 ]
Schlagenhaufer R. [1 ]
Bauer S. [2 ]
Szekeres T. [4 ]
Hamwi A. [4 ]
Fritzer-Szekeres M. [4 ]
Baumgartner C. [5 ]
Öngen H.Z. [6 ]
Güzelbey P. [6 ]
Roots I. [2 ]
Brinkmann U. [1 ]
机构
[1] Epidauros Biotechnology AG, Pharmacogenetics Laboratory, Bernried
[2] Institute of Clinical Pharmacology, University Medical Center Charité, Humboldt University, Berlin
[3] Department of Pharmacology, Medical Faculty, Pamukkale University, Denizli
[4] Institute of Clinical Chemistry, AKH-Wien, University of Vienna, Vienna
[5] Institute of Neurology, AKHWien, University of Vienna, Vienna
[6] Department of Pharmacology, University of Gaziantep
关键词
Pharmacogenetlcs; Polymorphism; TDM;
D O I
10.1038/sj.tpj.6500025
中图分类号
学科分类号
摘要
Phenytoin, an anticonvulsant, exhibits nonlinear pharmacokinetics with large interindividual differences. Because of its small therapeutic range with the risk of therapeutic failure or adverse drug effects in susceptible persons, therapeutic drug monitoring is frequently applied. The interindividual differences in dose response can partially be explained by known genetic polymorphisms in the metabolic enzyme CYP2C9 but a large deal of individual variability remains still unexplained. Part of this variability might be accounted for by variable uptake of phenytoin, which is a substrate of p-glycoprotein, encoded by the human MDR1 gene. We evaluated, whether phenytoin plasma levels correlate with a polymorphism in the MDR1 gene, C3435T, which is associated with intestinal PCP activity. Genotyping and analyses of plasma levels of phenytoin and metabolites in 96 healthy Turkish volunteers showed that the MDR1C > T3435 polymorphism affects phenytoin plasma levels (P = 0.064) and the metabolic ratio of p-HPPH vs phenytoin (MDR1*TT genotype, P = 0.026). The MDR1*CC genotype is more common in volunteers with low phenytoin levels (P ≤ 0.001, χ2 test). A combined analysis of variable alleles of CYP2C9, 2C19 and MDR1 revealed that the number of mutant CYP2C9 alleles is a major determinant, the number of MDR1*T alleles further contributes to the prediction of phenytoin plasma levels and CYP2C19*2 does not explain individual variability. The regression equation that fitted the data best included the number of mutant CYP2C9 and MDR*T alleles as predictory variables and explained 15.4% of the variability of phenytoin data (r2 = 0.154, P = 0.0002). Furthermore, analysis of CYP2C9 and MDR1 genotypes in 35 phenytoin-treated patients recruited from therapeutic drug monitoring showed that combined CYP2C9 and MDR1 analysis has some predictive value not only in the controlled settings of a clinical trial, but also in the daily clinical practice. © 2001 Nature Publishing Group All rights reserved.
引用
收藏
页码:204 / 210
页数:6
相关论文
共 50 条
  • [41] Human CYP2C-mediated stereoselective phenytoin hydroxylation in Japanese: Difference in chiral preference of CYP2C9 and CYP2C19
    Yasumori, T
    Chen, LS
    Li, QH
    Ueda, M
    Tsuzuki, T
    Goldstein, JA
    Kato, R
    Yamazoe, Y
    BIOCHEMICAL PHARMACOLOGY, 1999, 57 (11) : 1297 - 1303
  • [42] Genetic Polymorphisms and in Vitro Functional Characterization of CYP2C8, CYP2C9, and CYP2C19 Allelic Variants
    Hiratsuka, Masahiro
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2016, 39 (11) : 1748 - 1759
  • [43] Polymorphisms of CYP2C8, CYP2C9 and CYP2C19 and risk of coronary heart disease in Russian population
    Polonikov, Alexey
    Kharchenko, Alexander
    Bykanova, Marina
    Sirotina, Svetlana
    Ponomarenko, Irina
    Bocharova, Anna
    Vagaytseva, Kseniya
    Stepanov, Vadim
    Bushueva, Olga
    Churnosov, Mikhail
    Solodilova, Maria
    GENE, 2017, 627 : 451 - 459
  • [44] Effects of CYP2C19 and CYP2C9 polymorphisms on the efficacy and plasma concentration of lacosamide in pediatric patients with epilepsy in China
    Zhao, Ting
    Li, Hong-jian
    Zhang, Hui-lan
    Yu, Jing
    Feng, Jie
    Cui, Long
    Sun, Ke-Fang
    Sun, Yan
    Yu, Lu-hai
    EUROPEAN JOURNAL OF PEDIATRICS, 2024, 184 (01)
  • [45] Effects of CYP2C9 and MDR1 polymorphism on the pharmacokinetics of losartan
    Bae, Jung-Woo
    Han, Ho-Kyun
    Lee, Hwan-Joo
    Jung, Dong -Won
    Kim, Nam-Tae
    Lee, Jin-Hee
    Jang, Choon-Gon
    Choi, Sun-Ok
    Kim, Ok-Hee
    Lee, Seok-Yong
    ACTA PHARMACOLOGICA SINICA, 2006, 27 : 230 - 231
  • [46] Distribution of polymorphisms in the CYP2C9 gene and CYP2C19/CYP2C9 haplotypes among Venezuelan populations (vol 44, pg 191, 2016)
    Flores-Gutierrez, S.
    Rodriguez-Larralde, A.
    de Lugo, Vivenes M.
    de Guerra, Castro D.
    ANNALS OF HUMAN BIOLOGY, 2017, 44 (02) : I - I
  • [47] Individualized Phenytoin Therapy for Japanese Pediatric Patients With Epilepsy Based on CYP2C9 and CYP2C19 Genotypes
    Yamamoto, Yoshiaki
    Takahashi, Yukitoshi
    Imai, Katsumi
    Miyakawa, Kou
    Ikeda, Hiroko
    Ueda, Yuki
    Yamaguchi, Tokito
    Nasu, Hirosato
    Ohtani, Hideyuki
    Shigematsu, Hideo
    Kagawa, Yoshiyuki
    Inoue, Yushi
    THERAPEUTIC DRUG MONITORING, 2015, 37 (02) : 229 - 235
  • [48] Assessment of CYP2C9, CYP2C19, and CYP2D6 Polymorphisms in Allergic Patients with Chemical Sensitivity
    D'Attis, Simona
    Massari, Serafina
    Mazzei, Francesca
    Maio, Dominga
    Vergallo, Ilaria
    Mauro, Salvatore
    Minelli, Mauro
    Bozzetti, Maria Pia
    INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 2019, 179 (03) : 173 - 186
  • [49] Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance
    Scordo, MG
    Pengo, V
    Spina, E
    Dahl, ML
    Gusella, M
    Padrini, R
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 72 (06) : 702 - 710
  • [50] Glutathione S-Transferases CYP2C9 and CYP2C19 Polymorphisms in Turkish Children with Cancer
    Duzovali, Oznur
    Tamer, Lueluefer
    Ates, Nurcan A.
    Buyukdereli, Zekeriya
    Yildirim, Hatice
    Tasdelen, Bahar
    Yilgor, Esat
    Atik, Ugur
    UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, 2008, 18 (04): : 201 - +